Migraine and risk of cardiovascular disease in men.

PubWeight™: 2.49‹?› | Rank: Top 2%

🔗 View Article (PMID 17452542)

Published in Arch Intern Med on April 23, 2007

Authors

Tobias Kurth1, J Michael Gaziano, Nancy R Cook, Vadim Bubes, Giancarlo Logroscino, Hans-Christoph Diener, Julie E Buring

Author Affiliations

1: Divisions of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Mass 02215, USA. tkurth@rics.bwh.harvard.edu

Articles citing this

Migraine headache and ischemic stroke risk: an updated meta-analysis. Am J Med (2010) 3.06

Migraine and cardiovascular disease: a population-based study. Neurology (2010) 2.51

Migraine, vascular risk, and cardiovascular events in women: prospective cohort study. BMJ (2008) 2.48

Migraine frequency and risk of cardiovascular disease in women. Neurology (2009) 2.47

Migraine and mortality: a systematic review and meta-analysis. Cephalalgia (2011) 2.18

Migraine with aura and risk of cardiovascular and all cause mortality in men and women: prospective cohort study. BMJ (2010) 1.92

Body mass index, migraine, migraine frequency and migraine features in women. Cephalalgia (2009) 1.69

Age-specific association of migraine with cryptogenic TIA and stroke: Population-based study. Neurology (2015) 1.42

Interrelationships among the MTHFR 677C>T polymorphism, migraine, and cardiovascular disease. Neurology (2008) 1.41

Migraine in women: the role of hormones and their impact on vascular diseases. J Headache Pain (2012) 1.40

Population-based study of migraine in Spanish adults: relation to socio-demographic factors, lifestyle and co-morbidity with other conditions. J Headache Pain (2009) 1.18

Alcohol and migraine: trigger factor, consumption, mechanisms. A review. J Headache Pain (2008) 1.16

Migraine and cardiovascular disease: possible mechanisms of interaction. Neurology (2009) 1.14

The brain's heart - therapeutic opportunities for patent foramen ovale (PFO) and neurovascular disease. Pharmacol Ther (2013) 1.07

Comorbidities of migraine. Front Neurol (2010) 1.05

Comorbid neuropathologies in migraine: an update on cerebrovascular and cardiovascular aspects. J Headache Pain (2008) 1.05

New insights into the cardiovascular risk of migraine and the role of white matter hyperintensities: is gold all that glitters? J Headache Pain (2013) 1.02

Enalapril improves endothelial function in patients with migraine: A randomized, double-blind, placebo-controlled trial. J Res Med Sci (2011) 0.94

Migraine-associated risks and comorbidity. J Neurol (2008) 0.92

Migraine and risk of cardiovascular disease in women: prospective cohort study. BMJ (2016) 0.89

Migraine and stroke: "vascular" comorbidity. Front Neurol (2014) 0.87

Migraine, migraine features, and cardiovascular disease. Headache (2010) 0.85

Soluble CD40 ligand and prolactin levels in migraine patients during interictal period. J Headache Pain (2011) 0.84

The migraine association with cardiac anomalies, cardiovascular disease, and stroke. Neurol Clin (2009) 0.84

MTHFR 677C->T and ACE D/I polymorphisms and migraine attack frequency in women. Cephalalgia (2010) 0.84

Peripheral vascular dysfunction in migraine: a review. J Headache Pain (2013) 0.83

Migraine and cerebral infarction in young people. Neurol Sci (2009) 0.82

Association of Migraine and Sleep-Related Breathing Disorder: A Population-Based Cohort Study. Medicine (Baltimore) (2015) 0.81

Genetic determinants of cardiovascular events among women with migraine: a genome-wide association study. PLoS One (2011) 0.79

Migraine and heart rate variability. Arch Intern Med (2007) 0.79

Migraine and the risk of stroke: an updated meta-analysis of prospective cohort studies. Neurol Sci (2016) 0.78

[Pathophysiology of migraine and clinical implications]. Schmerz (2008) 0.77

Migraine, cerebrovascular disease and the metabolic syndrome. Ann Indian Acad Neurol (2012) 0.77

Migraine and hemorrhagic stroke: data from general practice. J Headache Pain (2015) 0.76

Migraine and cardiovascular diseases. Neurol Sci (2012) 0.76

[Current diagnosis and treatment of migraine]. Schmerz (2008) 0.76

Comorbidity of Migraine. Noro Psikiyatr Ars (2013) 0.75

Diagnostic value of nitroglycerin-induced headache as a negative predictor of coronary atherosclerosis. Chonnam Med J (2011) 0.75

Association between polymorphisms in the beta2-adrenoceptor gene and migraine in women. Headache (2008) 0.75

Thrombophilic disorders in migraine. Front Neurol (2014) 0.75

Factors associated with the differences in migraine prevalence rates between Spanish regions. ScientificWorldJournal (2014) 0.75

Endothelial Function in Patients with Migraine without Aura during the Interictal Period. Int J Prev Med (2015) 0.75

Headache in the presentation of noncephalic acute illness. J Neurosci Rural Pract (2016) 0.75

Cardiovascular disease risk in women with migraine. J Headache Pain (2013) 0.75

[Headache and migraine]. Nervenarzt (2007) 0.75

Migrainous infarction: association with vascular risk factors in a male subject. Neurol Sci (2009) 0.75

The Levels of Circulating Proangiogenic Factors in Migraineurs. Neuromolecular Med (2017) 0.75

Articles by these authors

Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med (2009) 39.97

A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med (2005) 17.32

Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med (2002) 16.23

Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. JAMA (2007) 15.32

Assessing the performance of prediction models: a framework for traditional and novel measures. Epidemiology (2010) 14.07

Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA (2008) 13.35

Vitamin E in the primary prevention of cardiovascular disease and cancer: the Women's Health Study: a randomized controlled trial. JAMA (2005) 12.09

Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. Lancet (2010) 11.25

Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA (2011) 11.02

Apixaban in patients with atrial fibrillation. N Engl J Med (2011) 9.97

Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA (2007) 9.68

Stent-retriever thrombectomy after intravenous t-PA vs. t-PA alone in stroke. N Engl J Med (2015) 9.58

Statins: new American guidelines for prevention of cardiovascular disease. Lancet (2013) 9.56

Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial. JAMA (2005) 9.03

Vitamins E and C in the prevention of cardiovascular disease in men: the Physicians' Health Study II randomized controlled trial. JAMA (2008) 8.32

Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet (2015) 7.99

Long term effects of dietary sodium reduction on cardiovascular disease outcomes: observational follow-up of the trials of hypertension prevention (TOHP). BMJ (2007) 7.54

C-reactive protein and parental history improve global cardiovascular risk prediction: the Reynolds Risk Score for men. Circulation (2008) 7.33

Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med (2008) 7.25

C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation (2003) 6.99

Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation (2011) 6.48

Effects of lowering homocysteine levels with B vitamins on cardiovascular disease, cancer, and cause-specific mortality: Meta-analysis of 8 randomized trials involving 37 485 individuals. Arch Intern Med (2010) 6.48

C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med (2012) 6.39

Soft drink consumption and risk of developing cardiometabolic risk factors and the metabolic syndrome in middle-aged adults in the community. Circulation (2007) 6.34

Relations of serum phosphorus and calcium levels to the incidence of cardiovascular disease in the community. Arch Intern Med (2007) 6.29

Results of multivariable logistic regression, propensity matching, propensity adjustment, and propensity-based weighting under conditions of nonuniform effect. Am J Epidemiol (2005) 6.20

Migraine and risk of cardiovascular disease in women. JAMA (2006) 6.16

Sex hormone-binding globulin and risk of type 2 diabetes in women and men. N Engl J Med (2009) 6.16

Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990-2013: quantifying the epidemiological transition. Lancet (2015) 6.13

Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med (2008) 6.08

Cardiovascular disease risk prediction with and without knowledge of genetic variation at chromosome 9p21.3. Ann Intern Med (2009) 6.00

Hemoglobin A1c predicts diabetes but not cardiovascular disease in nondiabetic women. Am J Med (2007) 5.95

Effect of folic acid and B vitamins on risk of cardiovascular events and total mortality among women at high risk for cardiovascular disease: a randomized trial. JAMA (2008) 5.92

C-reactive protein and the risk of developing hypertension. JAMA (2003) 5.75

Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women. JAMA (2005) 5.74

The effect of including C-reactive protein in cardiovascular risk prediction models for women. Ann Intern Med (2006) 5.69

Laboratory-based versus non-laboratory-based method for assessment of cardiovascular disease risk: the NHANES I Follow-up Study cohort. Lancet (2008) 5.49

Cryptogenic stroke and underlying atrial fibrillation. N Engl J Med (2014) 5.44

NXY-059 for acute ischemic stroke. N Engl J Med (2006) 5.32

Measures of obesity and cardiovascular risk among men and women. J Am Coll Cardiol (2008) 5.28

Physical activity and weight gain prevention. JAMA (2010) 5.27

Multivitamins in the prevention of cancer in men: the Physicians' Health Study II randomized controlled trial. JAMA (2012) 5.25

Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer. Nat Genet (2009) 5.14

Vitamins E and C in the prevention of prostate and total cancer in men: the Physicians' Health Study II randomized controlled trial. JAMA (2008) 5.13

Migraine and cardiovascular disease: systematic review and meta-analysis. BMJ (2009) 4.98

Adherence to a DASH-style diet and risk of coronary heart disease and stroke in women. Arch Intern Med (2008) 4.98

Inactivating mutations in NPC1L1 and protection from coronary heart disease. N Engl J Med (2014) 4.94

A genome-wide association study identifies pancreatic cancer susceptibility loci on chromosomes 13q22.1, 1q32.1 and 5p15.33. Nat Genet (2010) 4.89

Risk of death and cardiovascular events in initially healthy women with new-onset atrial fibrillation. JAMA (2011) 4.73

Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trial. JAMA (2007) 4.60

Pharmacogenetic study of statin therapy and cholesterol reduction. JAMA (2004) 4.47

Association between a literature-based genetic risk score and cardiovascular events in women. JAMA (2010) 4.46

Prevalence of dry eye syndrome among US women. Am J Ophthalmol (2003) 4.46

Rationale, design, and methodology of the Women's Genome Health Study: a genome-wide association study of more than 25,000 initially healthy american women. Clin Chem (2007) 4.45

Multivitamins in the prevention of cardiovascular disease in men: the Physicians' Health Study II randomized controlled trial. JAMA (2012) 4.40

Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med (2004) 4.39

OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache (2010) 4.37

Loci related to metabolic-syndrome pathways including LEPR,HNF1A, IL6R, and GCKR associate with plasma C-reactive protein: the Women's Genome Health Study. Am J Hum Genet (2008) 4.31

A comprehensive care management program to prevent chronic obstructive pulmonary disease hospitalizations: a randomized, controlled trial. Ann Intern Med (2012) 4.10

Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women. Circulation (2009) 3.93

New models for large prospective studies: is there a better way? Am J Epidemiol (2012) 3.85

Childhood blood pressure trends and risk factors for high blood pressure: the NHANES experience 1988-2008. Hypertension (2013) 3.81

Genome-wide association studies identify four ER negative-specific breast cancer risk loci. Nat Genet (2013) 3.81

NXY-059 for the treatment of acute ischemic stroke. N Engl J Med (2007) 3.70

Prognostication after cardiac arrest and hypothermia: a prospective study. Ann Neurol (2010) 3.70

Detectable clonal mosaicism and its relationship to aging and cancer. Nat Genet (2012) 3.69

Meta-analysis of genome-wide association studies in >80 000 subjects identifies multiple loci for C-reactive protein levels. Circulation (2011) 3.68

Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis. Lancet Oncol (2008) 3.62